Bija Ventures: Deal-by-deal access to the cures for humanity's most devastating diseases.
Bypassing the mouse to invest in the human.
The traditional biotech playbook struggles to defeat humanity’s greatest threats because it takes forever. Capital is locked up for a decade, burning through billions on early-stage biology that fails in mice.
We bypass the early-stage discovery gamble entirely. Today, AI makes it easy to discover drug blueprints quickly and in abundance. But translating that blueprint into a physical human trial is the ultimate bottleneck. Bija steps in exactly at that bottleneck. We fund the final operational sprint to get a breakthrough into human trials—delivering the exact clinic-ready therapeutics Big Pharma is desperate to buy.
Why Bija? Scientists. Operators. Investors.
Deep tech and biotech are black boxes for most investors. We do the heavy lifting of institutional-grade diligence, so you don't have to.
- Preclinical Rigor: Our GPs (Nelly Weiser & Colin Maraganore) are a Stanford-trained bioengineer and a serial translational scientist, respectively, who helped to build the operational scaffolding at elite biotechs. We don't just syndicate; we scrutinize. Every deal undergoes 40+ hours of institutional-grade diligence to separate elite, de-risked biology from TechBio hype.
- Institutional Access: We leverage an active network of over 250 VC firms to secure allocations in oversubscribed rounds. We don't guess what Big Pharma wants—we talk to them, and we fund exactly what they are waiting to buy.
- Scale & Capital Efficiency: Supported by Ishtpreet Singh (current Strategy & Ops leadership at Waymo and former Google Ventures staff), our syndicate back-office runs with institutional precision.
The Track Record & The Impact
Across our careers, our team has collectively deployed capital into 53 companies representing $56B+ in aggregate value (including generational AI outliers like Perplexity).
At Bija, we apply that elite investing acumen exclusively to the future of medicine. We target actual cures, not incremental baby steps. Our active portfolio includes:
- Fauna Bio: Treating heart failure with insights from hibernating squirrels.
- Modulate Bio: Silencing severe, age-related movement disorders.
- Coding Bio: Targeting cancer in patients with zero remaining options.
- Novoron: Pioneering a radically new approach to Alzheimer’s and Parkinson’s.
Institutional access. Angel minimums.
The Bija Syndicate gives you ultimate control over your capital. Review our institutional diligence memo for each company and invest only in the cures you care about, for as little as $1,000 per deal.
Join us in fast-tracking cures in our lifetime.
